TABLE 2.
The results of multivariable analysis
| Variable | Odds Ratio | SE | P value | 95% Conf. interval for OR | |
|---|---|---|---|---|---|
| Predicting presence of PCa | |||||
| Age | 1.018 | 0.015 | .210 | 0.998 | 1.049 |
| 4K score test (OPKO Diagnostics, Woburn, MA) | 1.033 | 0.006 | .000 | 1.020 | 1.047 |
| DRE | 0.971 | 0.226 | .900 | 0.614 | 1.535 |
| Prior negative biopsy | 0.492 | 0.125 | .006 | 0.298 | 0.813 |
| Prostate volume | 0.978 | 0.004 | .000 | 0.970 | 0.987 |
| MRI PI‐RADS score | |||||
| 3 | 2.114 | 0.641 | .014 | 1.166 | 3.831 |
| 4 | 4.402 | 1.106 | .000 | 2.690 | 7.203 |
| 5 | 9.235 | 4.028 | .000 | 3.927 | 21.716 |
| Predicting presence of csPCa | |||||
| Age | 1.021 | 0.019 | .267 | 0.983 | 1.060 |
| 4K score test (OPKO Diagnostics, Woburn, MA) | 1.033 | 0.006 | .000 | 1.020 | 1.047 |
| DRE | 1.397 | 0.381 | .220 | 0.818 | 2.386 |
| Prior negative biopsy | 0.288 | 0.111 | .001 | 0.135 | 0.616 |
| Prostate volume | 0.977 | 0.054 | .000 | 0.967 | 0.988 |
| MRI PI‐RADS score | |||||
| 3 | 2.650 | 1.187 | .030 | 1.102 | 6.378 |
| 4 | 8.366 | 2.894 | .000 | 4.246 | 16.483 |
| 5 | 18.702 | 8.512 | .000 | 7.664 | 45.639 |
| Predicting presence of uPCa | |||||
| Age | 1.072 | 0.024 | .002 | 1.026 | 1.119 |
| 4K score test (OPKO Diagnostics, Woburn, MA) | 1.024 | 0.007 | .000 | 1.011 | 1.038 |
| DRE | 1.472 | 0.463 | .219 | 0.794 | 2.727 |
| Prior negative biopsy | 0.189 | 0.109 | .004 | 0.060 | 0.587 |
| Prostate volume | 0.994 | 0.004 | .211 | 0.985 | 1.003 |
| MRI PI‐RADS score | |||||
| 3 | 1.767 | 1.196 | .401 | 0.468 | 6.666 |
| 4 | 7.338 | 3.531 | .000 | 2.856 | 18.846 |
| 5 | 13.670 | 7.462 | .000 | 4.689 | 39.849 |
Abbreviations: csPCa, clinically significant prostate cancer; DRE, digital rectal examination finding; PCa, prostate cancer; PI‐RADS, Prostate Imaging Reporting and Data System; uPCa, unfavorable prostate cancer.